GENOMIC PREDICTORS OF CLINICAL OUTCOMES AND BENEFIT OF (CHEMO)HORMONAL THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER.

Dana-Farber Cancer Institute, Inc.

Investigators